Drug Trial Radar · NCT06064812
A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
99
Planned (sponsor's estimate)
Start
Sep 12, 2023
Primary completion
Mar 2026
Study completion Mar 2028
Sponsor
- Lead sponsor
- Forward Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I/II, Open-label study to assess the safety, tolerability, pharmacokinetic, and antitumor efficacy of FWD1802 monotherapy in patients with ER+/HER2- unresectable locally advanced or metastatic breast cancer. This clinical trial aims to explore the role of FWD1802 in the ER+/HER2- advanced breast cancer patient population. The primary objectives are to address the following questions: Phase I Study: Determine the Recommended Phase II Dose (RP2D) and/or Maximum Tolerated Dose (MTD) of FWD1802 in patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer. Phase II Study: To evaluate the efficacy of FWD1802 at the RP2D in patients with ESR1-mutated ER-positive/HER2-negative locally advanced or metastatic breast cancer, using objective response rate (ORR) as the efficacy endpoint.
Conditions
- Metastatic Breast Cancer
- Locally Advanced Breast Cancer
- Breast Cancer Stage IV
- ER+/HER2- Breast Cancer
Interventions
FWD1802Drug
Eligible subjects will receive FWD1802 treatment according to their assigned dose cohort. Dose Escalation Phase: This phase is divided into a Single-Agent Lead-in Period (C0) and a Multiple-Dosing Period (C1). During the single-agent lead-in period, subjects will receive one dose on Day 1, followed by a 6-day dosing pause. In the multiple-dosing period, subjects will be administered FWD1802 once daily. Dose Expansion Phase: Subjects will receive FWD1802 once daily. Each 4-week period constitutes one treatment cycle. Treatment will continue for up to 2 years or until one of the following events occurs (whichever comes first): disease progression, intolerable toxicity, withdrawal of informed consent, loss to follow-up, initiation of new anti-cancer therapy, or death. Patients who remain in the study at the end of the 2-year treatment period and continue to derive clinical benefit may, upon agreement between the investigator and the sponsor, have the option to continue treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I StudyTime frame: Approximately 2 years
- Phase II StudyTime frame: Approximately 2 years
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
The Second Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Huizhou First Hospital
Huizhou, Guangdong, China · Recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China · Recruiting
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, Henan, China · Recruiting
Xinxiang Central Hospital
Xinxiang, Henan, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Not yet recruiting
Hubei Cancer Hospital
Wuhan, Hubei, China · Not yet recruiting
The Central Hospital of Yongzhou
Yongzhou, Hunan, China · Recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Recruiting
Jilin Cancer Hospital
Changchun, Jilin, China · Recruiting
The First Hospital of Jilin University
Changchun, Jilin, China · Recruiting
First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China · Recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Sichuan Cancer Hospital
Chengdu, Sichuan, China · Recruiting
The second people's hospital of Yibin
Yibin, Sichuan, China · Recruiting
Tianjin Medical University Cancer institute & Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Sir Run Run Shaw Hospital,affiliated with Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.